Recombinant Human B7-H4 His Tagged Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human B7-H4 His Tagged Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED₅₀ for this effect is 0.5‑2.5 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human B7-H4 protein
  Phe29-Ala258, with a C-terminal 10-His tag
• Accession #: NP_078902
• N-terminal Sequence: Phe29
• Protein/Peptide Type: Recombinant Proteins
• Gene: VTCN1
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 26.7 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 45-60 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human B7-H4 His Tagged Protein, CF

• B7h.5
• B7H4
• B7-H4
• B7H4T-cell costimulatory molecule B7x
• B7S1
• B7S1VCTN1
• B7x
• B7XPRO1291
• FLJ22418
• Immune costimulatory protein B7-H4
• Protein B7S1
• T cell costimulatory molecule B7x
• V-set domain containing T cell activation inhibitor 1
• V-set domain-containing T-cell activation inhibitor 1
• Vtcn1

Background

B7-H4, also known as VTCN1, B7x and B7S1, is a 50 ‑ 80 kDa glycosylated member of the BTN/MOG family of immunomodulatory protein (1, 2). Mature human B7-H4 consists of a 235 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain, a 21 aa transmembrane segment, and a 2 aa cytoplasmic tail (3 - 5). Within the ECD, human B7-H4 shares 90% aa sequence identity with mouse and rat B7-H4. It shares 22% - 28% aa sequence identity with human B7-1, B7-2, B7-H1, B7-H2, B7-H3, and PD‑L2. Alternate splicing of human B7-H4 generates an additional isoform that lacks the first Ig-like domain. B7-H4 is expressed on the surface of activated lymphocytes, macrophages, monocytes, dendritic cells, epithelial cells, and bone marrow-derived mesenchymal stem cells (4 - 8). Following binding to activated T cells, B7-H4 serves as a co‑inhibitor of the T cell response. This is accomplished by reverse signaling that can induce either cell cycle arrest, or apoptosis in B7-H4 expressing cells (3 - 5, 9, 10). B7‑H4 is up‑regulated in several carcinomas in correlation with tumor progression and metastasis (2, 7, 11, 12). A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status (13 - 15). Soluble B7‑H4 functions as a decoy molecule that blocks the inhibitory influence of B7‑H4 on immune activation (15). Despite evidence for the involvement of B7-H4 in immune regulation, mice deficient in its expression do not show significant immune deficiencies, suggesting compensation by other molecules in vivo (16).

1. Yi, K.H. and L. Chen (2009) Immunol. Rev. 229:145.
2. Salceda, S. et al. (2005) Exp. Cell Res. 306:128.
3. Zang, X. et al. (2003) Proc. Natl. Acad. Sci. 100:10388.
4. Prasad, V.R. et al. (2003) Immunity 18:863.
5. Sica, G.L. et al. (2003) Immunity 18:849.
6. Kryczek, I. et al. (2006) J. Exp. Med. 203:871.
7. Tringler, B. et al. (2005) Clin. Cancer Res. 11:1842.
8. Xue, Q. et al. (2010) Stem Cells Dev. 19:27.
9. Song, H. et al. (2008) Cancer Lett. 266:227.
10. Park, G.B. et al. (2009) Immunology 128:360.
11. Zang, X. et al. (2007) Proc. Natl. Acad. Sci. 104:19458.
12. Krambeck, A.E. et al. (2006) Proc. Natl. Acad. Sci. 103:10391.
13. Simon, I. et al. (2006) Cancer Res. 66:1570.
14. Thompson, R.H. et al. (2008) Cancer Res. 68:6054.
15. Azuma, T. et al. (2009) PloS Med. 6:e1000166.
16. Suh, W.-K. et al. (2006) Mol. Cell. Biol. 26:6403.

Publications for B7-H4 (6576-B7)(3)

Publications using 6576-B7

• Ma, Y;Duan, L;Reisch, B;Kimmig, R;Iannaccone, A;Gellhaus, A; Impact of the Immunomodulatory Factor Soluble B7-H4 in the Progress of Preeclampsia by Inhibiting Essential Functions of Extravillous Trophoblast Cells Cells 2024-08-17 [PMID: 39195262] (Bioassay, Human)
• Toader, D;Fessler, SP;Collins, SD;Conlon, PR;Bollu, R;Catcott, KC;Chin, CN;Dirksen, A;Du, B;Duvall, JR;Higgins, S;Kozytska, MV;Bellovoda, K;Faircloth, C;Lee, D;Li, F;Qin, L;Routhier, C;Shaw, P;Stevenson, CA;Wang, J;Wongthida, P;Ter-Ovanesyan, E;Ditty, E;Bradley, SP;Xu, L;Yin, M;Yurkovetskiy, AV;Mosher, R;Damelin, M;Lowinger, TB; Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer Molecular cancer therapeutics 2023-06-09 [PMID: 37294948] (ELISA Capture, Human)
• A Garg, R Trout, SA Spector Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4 Sci Rep, 2017-03-24;7(0):44485. 2017-03-24 [PMID: 28338007] (Bioassay, Human)

Bioinformatics

• Gene Symbol: VTCN1
• Uniprot:
  • NP_078902()